Literature DB >> 6111409

Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension.

R Larsson, B E Karlberg, B Norlander, A Wirsén.   

Abstract

Single oral doses of 1.5, 3.0, 4.5 and 6.0 mg/kg prizidilol HCl, an antihypertensive with vasodilator and beta-adrenoceptor blocking actions, were given to 12 patients with primary hypertension on separate days. Systolic and diastolic blood pressure (BP) decreased after 4.5 and 6.0 mg/kg and systolic BP also after 3.0 mg/kg. The antihypertensive effect was evident in 1 to 2 hr with maximum effect in 4 to 5 hr (supine systolic BP 20 and diastolic 13 mm Hg after 6.0 mg/kg); the effect was sustained for more than 8 hr. An initial slight reduction in heart rate (HR) after 1 to 2 hr was followed by a slight rise after 6 to 8 hr. There were higher plasma drug levels and greater antihypertensive effects after the 6.0-mg/kg dose in slow acetylators (n = 5) than in rapid acetylators (n = 7). Due to its hydrazine moiety, prizidilol, like hydralazine, seems to be a substrate for the polymorphic N-acetyltransferase enzyme system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6111409     DOI: 10.1038/clpt.1981.82

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  The place of alpha-adrenoceptor and beta-adrenoceptor blockade in the treatment of hypertension.

Authors:  F Gross
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

2.  Comparison of the effects of prizidilol and propranolol on renal haemodynamics at rest and during exercise.

Authors:  P L Malini; E Strocchi; E Ambrosioni
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

3.  Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.

Authors:  M G Bianchetti; K Boehringer; P Weidmann; L Link; H Schiffl; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

4.  Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.

Authors:  T Lüscher; J Havelka; P Greminger; J Tuma; M Täuber; W Siegenthaler; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis.

Authors:  R N Hobbs; A L Clayton; R M Bernstein
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

6.  Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.

Authors:  B E Karlberg; R Larsson; K P Ohman; B Norlander; A Wirsen; J Hed; B L Lundh; A Flock
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function.

Authors:  K Boehringer; P Weidmann; L Link; M G Bianchetti; H Schiffl; F C Reubi
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.